Quarterly ResultMay 13, 2026, 04:37 PM
Rapid Micro Biosystems Q1 Revenue +11% to $8.0M; Net Loss $14.3M
AI Summary
Rapid Micro Biosystems reported an 11.1% increase in total revenue to $8.0 million for the first quarter of 2026, driven by strong product revenue growth of 36.0% and a 27.7% rise in recurring revenue. The company placed 6 Growth Direct systems, doubling the placements from the prior year, and saw significant improvements in product and consumable gross margins. Despite these operational gains, the net loss widened to $14.3 million, or $0.31 per share, and cash reserves decreased. The company reaffirmed its full year 2026 revenue and system placement guidance.
Key Highlights
- Q1 2026 total revenue increased 11.1% to $8.0 million compared to $7.2 million in Q1 2025.
- Product revenue grew 36.0% to $5.6 million; recurring revenue increased 27.7% to $5.1 million.
- The company placed 6 Growth Direct systems in Q1 2026, up from 3 systems in Q1 2025.
- Product gross margin percentage increased 15-percentage points; consumable gross margin increased 33-percentage points.
- Net loss for Q1 2026 was $14.3 million, or $0.31 per share, compared to $11.3 million in Q1 2025.
- Reaffirmed full year 2026 total revenue guidance of $37.0 million to $41.0 million.
- Reaffirmed full year 2026 guidance for 30 to 38 Growth Direct system placements and approximately 20% gross margin.
- Cash, cash equivalents, short-term investments, and restricted cash totaled $23.2 million as of March 31, 2026.
Price Impact
More from RPID